FIELD: chemistry.
SUBSTANCE: invention relates to a compound represented by structural formula (I-2), or a pharmaceutically acceptable salt thereof or a stereoisomer thereof. In formula (I-2), A is CR2 or N; (i) R is 
, where the 
bond connects to the pyrimidine ring, each case Ra independently is H, F or Cl; Ra1 independently is H, C1-4 alkyl or C1-4 hydroxyalkyl; Ra1' independently is -(CHRaa)kOH, -(CHRaa)kCN, -(CHRaa)kC(O)OR11, -(CHRaa)kC(O)NR11R12, -(CHRaa)kC(O)NR11OR12, -(CHRaa)kC(O)NR11S(=O)2R12, -(CHRaa)kS(=O)2R11, -(CHRaa)kS(=O)2NR11R12, -(CHRaa)kNR11S(=O)2R12, -(CHRaa)k-5–6-member heteroaryl or -(CHRaa)kP(=O)R11R12; Raa is independently H or C1-3 alkyl, optionally substituted with halogen; R1 is H, deuterium, halogen, CN, NH2, NO2 or C1-6 alkyl, optionally substituted with one to three halogens; or (ii) R and R1, together with carbon atoms to which they are bonded, form a ring represented below: 
, 
, 
, 
or 
, where bonds are bonded with pyrimidine ring; each occurrence of R b is independently H, deuterium, halogen, CN, COOH or P(=O)R11R12; each case Rc is independently phenyl, 5–6 membered monocyclic heteroaryl having 1–3 heteroatoms selected from N; wherein the phenyl or heteroaryl represented by Rc, is optionally substituted with one to three substituents independently selected from the group consisting of C1-4 alkyl, C1-4 haloalkyl, C(O)NR11R12 and P(O)di-C1-6 alkyl; each case R2 is independently H, deuterium, halogen or C1-6 alkoxy; R3 is H, C1-6 alkyl or C(O)C1-6 alkyl, where the alkyl represented by R3 or in the group represented by R3, is optionally substituted with one to three substituents independently selected from the group consisting of halogen, OH, C1-4 alkyl and NR11R12; each case R11 and R12 is independently H or C1-6 alkyl, where the alkyl represented by R11 or R12, is optionally substituted with one to three substituents independently selected from the group consisting of CN and C1-4 alkyl; m is 0, 1, 2 or 3; and k is equal to 0 or 1. Invention also discloses a compound of formula (II), or a pharmaceutically acceptable salt thereof, wherein the values of the variables in formula (II) are such as given in the claims; a compound selected from a group of individual compounds; a pharmaceutical composition based on said compounds; method of treating cancer using said compounds.
EFFECT: disclosed compounds are HPK1 activity inhibitors and can be used to treat cancer mediated by HPK1 activity.
34 cl, 2 tbl, 177 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOUNDS FOR INHIBITING KINASE EGFR, METHODS FOR PRODUCTION AND USE THEREOF | 2020 |
|
RU2832925C2 |
| N2-(2-PHENYL)-PYRIDO[3,4-D]PYRIMIDINE-2,8-DIAMINE DERIVATIVES AND USE THEREOF AS MPS1 INHIBITOR | 2015 |
|
RU2693460C2 |
| ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF FOR INHIBITING NOREPINEPHRINE, DOPAMINE AND SEROTONIN REUPTAKE | 2005 |
|
RU2388751C2 |
| PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | 2020 |
|
RU2833220C2 |
| HETEROCYCLIC DERIVATIVES AND USE THEREOF | 2015 |
|
RU2734390C2 |
| 2,6-SUBSTUTED-4-MONOSUBSTITUTED AMINO-PYRIMIDINES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | 2005 |
|
RU2417990C2 |
| SELECTIVE KINASE JAK1 INHIBITOR | 2020 |
|
RU2818002C2 |
| TETRAHYDROISOQUINOLINE COMPOUND, ITS PRODUCTION METHOD, PHARMACEUTICAL COMPOSITION CONTAINING SUCH A COMPOUND, AND ITS USE | 2019 |
|
RU2792034C2 |
| SUBSTITUTED CARBONUCLEOSIDES DERIVATIVES USED AS ANTICANCER AGENTS | 2017 |
|
RU2712944C1 |
| METHOD FOR OBTAINING AROMATIC HETEROCYCLIC COMPOUND USED AS SELECTIVE INHIBITOR OF KINASE JAK1 AND APPLICATION THEREOF | 2015 |
|
RU2671195C2 |
